Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Public Payer Lowers Expectations As Record Novel Drugs Gain Approvals

Executive Summary

Cost concerns and an increased number of potential entrants will dominate the annual adjustments to China's the national reimbursement drug list, with regulators moving to manage companies' expectations. 

You may also be interested in...



HutchMed CEO On Novel Drug Pricing Strategy In China

A successful IPO on the Hong Kong Stock Exchange will jump-start the company’s R&D and new drug approvals, says HutchMed's CEO in an interview.

Two Chinese IPOs Kickstart A Hectic Biotech Fundraising Season

Two IPOs and 12 venture capital and private equity deals in China raised a combined $1bn in a hectic few weeks of October.

ADC Competition Heats Up In China But Caution, Pressure Also Mount

After the anti-PD-1/L1 antibody and cell therapy rush, antibody-drug conjugates are quickly gaining attention in China as new technologies and deal-making activity heats up, but one first mover warns of potential over-crowding.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel